Voloshyna I - Search Results

1

Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux.

Voloshyna I, Teboul I, Littlefield MJ, Siegart NM, Turi GK, Fazzari MJ, Carsons SE, DeLeon J, Reiss AB. Voloshyna I, et al. Exp Biol Med (Maywood). 2016 Aug;241(14):1611-9. doi: 10.1177/1535370216647181. Epub 2016 Apr 27. Exp Biol Med (Maywood). 2016. PMID: 27190277 Free PMC article.

2

Plasma IL-33 in atopic patients correlates with pro-inflammatory cytokines and changes cholesterol transport protein expression: a surprising neutral overall impact on atherogenicity.

Voloshyna I, Mucci T, Sher J, Fonacier LS, Littlefield MJ, Carsons S, Reiss AB. Voloshyna I, et al. Clin Exp Allergy. 2015 Oct;45(10):1554-65. doi: 10.1111/cea.12516. Clin Exp Allergy. 2015. PMID: 25703059 Clinical Trial.

3

Resveratrol in cholesterol metabolism and atherosclerosis.

Voloshyna I, Hussaini SM, Reiss AB. Voloshyna I, et al. J Med Food. 2012 Sep;15(9):763-73. doi: 10.1089/jmf.2012.0025. Epub 2012 Aug 2. J Med Food. 2012. PMID: 22856383 Review.

4

Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine.

Voloshyna I, Hai O, Littlefield MJ, Carsons S, Reiss AB. Voloshyna I, et al. Eur J Pharmacol. 2013 Jan 5;698(1-3):299-309. doi: 10.1016/j.ejphar.2012.08.024. Epub 2012 Oct 4. Eur J Pharmacol. 2013. PMID: 23041272

5

Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages.

Voloshyna I, Modayil S, Littlefield MJ, Belilos E, Belostocki K, Bonetti L, Rosenblum G, Carsons SE, Reiss AB. Voloshyna I, et al. Exp Biol Med (Maywood). 2013 Oct;238(10):1192-7. doi: 10.1177/1535370213503262. Epub 2013 Sep 2. Exp Biol Med (Maywood). 2013. PMID: 24000379 Free PMC article.

6

Infliximab reverses suppression of cholesterol efflux proteins by TNF-α: a possible mechanism for modulation of atherogenesis.

Voloshyna I, Seshadri S, Anwar K, Littlefield MJ, Belilos E, Carsons SE, Reiss AB. Voloshyna I, et al. Biomed Res Int. 2014;2014:312647. doi: 10.1155/2014/312647. Epub 2014 Jan 23. Biomed Res Int. 2014. PMID: 24587984 Free PMC article.

7

Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy.

Reiss AB, Arain HA, Kasselman LJ, Renna HA, Zhen J, Voloshyna I, DeLeon J, Carsons SE, Petri M. Reiss AB, et al. Among authors: voloshyna i. Medicina (Kaunas). 2019 Aug 21;55(9):514. doi: 10.3390/medicina55090514. Medicina (Kaunas). 2019. PMID: 31438615 Free PMC article.

8

Effect of inhibition of interleukin-12/23 by ustekinumab on the expression of leptin and leptin receptor in human THP-1 macrophages.

Voloshyna I, Mounessa J, Carsons SE, Reiss AB. Voloshyna I, et al. Clin Exp Dermatol. 2016 Apr;41(3):308-11. doi: 10.1111/ced.12699. Epub 2015 Jun 20. Clin Exp Dermatol. 2016. PMID: 26095599 Free PMC article.

9

COX-2 inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell formation in THP-1 cells.

Anwar K, Voloshyna I, Littlefield MJ, Carsons SE, Wirkowski PA, Jaber NL, Sohn A, Eapen S, Reiss AB. Anwar K, et al. Among authors: voloshyna i. Lipids. 2011 Feb;46(2):131-42. doi: 10.1007/s11745-010-3502-4. Epub 2010 Dec 22. Lipids. 2011. PMID: 21181286

10

The ABC transporters in lipid flux and atherosclerosis.

Voloshyna I, Reiss AB. Voloshyna I, et al. Prog Lipid Res. 2011 Jul;50(3):213-24. doi: 10.1016/j.plipres.2011.02.001. Epub 2011 Feb 23. Prog Lipid Res. 2011. PMID: 21352852 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters